NE-ADJUVANCE-TECH
24.8.2021 16:02:08 CEST | Business Wire | Press release
Adjuvance Technologies Inc., a privately held clinical-stage biopharmaceutical company developing saponin adjuvants and vaccines for infectious disease and immuno-oncology, announced that its adjuvant TQL-1055 was safe and well-tolerated with a co-administered pertussis vaccine. This is the first clinical trial of a candidate from the company’s adjuvant and vaccine portfolio.
“The usefulness of saponin adjuvants has been constrained by dose-limiting tolerability and manufacturing challenges. Our semi-synthetic molecule is designed to overcome these limitations,” said Tyler Martin M.D., Chief Executive Officer at Adjuvance. “These promising interim results demonstrate the potential of TQL-1055, including its ability to be used in a broader dose-range without compromising its excellent tolerability.”
Interim data from the trial show that TQL-1055 was generally well tolerated across all dose levels, with an overall safety profile similar to a commercial pertussis vaccine. Solicited events reported by subjects included mild to moderate injection site reactions and mild or moderate systemic symptoms at a frequency similar to the commercial vaccine. No serious adverse events were reported.
The ongoing phase 1, randomized, double-blind, active-controlled, dose-escalation study is assessing the safety and immunogenicity of P ertussis A cellular V accine A djuvanted with TQL-1055 (PAVA). It has fully enrolled 72 healthy adults 18-50 years of age and is evaluating six escalating dose levels from 25 to 800 mcg of TQL-1055, co-administered with a commercial pertussis vaccine. The primary endpoints of the study are safety and tolerability. Further data will be presented at IDWeek 2021.
About Pertussis: Commonly known as whooping cough, pertussis is a respiratory illness that spreads from person to person. Vaccination against pertussis occurs throughout life and is recommended in many countries for all children and adults. Reported annual cases of pertussis in the United States have increased 10-fold between the 1970s and 2010s, revealing the need for more effective vaccines and vaccination.
About TQL-1055 : TQL-1055 is a rationally designed, semi-synthetic analogue of the saponin adjuvant QS-21 that is designed to have improved tolerability and provide the same strong immune response as QS-21. Adjuvance has retained the desirable properties of, and eliminated several challenges with QS-21. TQL-1055 is a semi-synthetic molecule whose efficient synthesis uses raw material from leaves and branches of the Quillaja saponaria tree, making it available in greater quantities than the source material for other saponin adjuvants. TQL-1055 has shown favorable tolerability and a strong immune response in a clinical trial. With TQL-1055 as the foundation, Adjuvance is designing new combination adjuvants to produce different types of immune responses.
About saponin adjuvants : Saponin adjuvants are potent immune stimulators and important components of licensed and clinically-advanced infectious disease vaccines including those against shingles, malaria, COVID-19 and influenza. Saponin adjuvants have also been studied in immuno-oncology applications. Existing saponin adjuvants are limited by poor clinical tolerability and inefficient manufacturing requirements. The natural source material in most saponin adjuvants is extracted from the inner lining of the bark of the Quillaja saponaria tree, resulting in a terminal harvest.
About Adjuvance Technologies : Adjuvance Technologies is a privately held clinical-stage biopharmaceutical company dedicated to empowering health through fundamental breakthroughs in adjuvant design, vaccine development, and manufacturing. Adjuvance creates and manufactures next generation proprietary adjuvants as the foundation of its vaccine pipeline and for other developers through licensing partnerships. Our vaccine candidates in pertussis and herpes zoster aim to provide a better experience for the recipient and the same protection against disease.
Headquartered in Lincoln, Nebraska, the company has received grant funding from the National Institute of Health (NIH) and closed a Series A investment by Morningside Venture Investments. For more information, visit www.adjuvancetechnologies.com and connect with us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210824005212/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nexthop AI Unveils Transformative, industry-leading Scale-out and Scale-across Switches engineered for Hyperscalers & NeoClouds10.3.2026 13:45:00 CET | Press release
Underlines focus on power efficient solutions, deployment velocity and open networking Nexthop AI, the leading pioneer of highly efficient AI Networking, today launched a range of products for scale-out, scale-across and front-end applications for cloud and AI datacenters. The launch portfolio sets new standards for performance, power efficiency, and deployment speed - very critical metrics in AI infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310990709/en/ Nexthop AI's highly efficient scale-out and scale-across AI networking portfolio Nexthop also unveiled the Disaggregated Spine architecture - a new, highly efficient, scale-across network design developed in collaboration with a large hyperscaler. This innovative architecture decomposes the traditional monolithic chassis running proprietary software into independent, optimized, functional tiers. It features a scale-across leaf tier (data center fabric fa
Nexthop AI Accelerates Into Hypergrowth With Oversubscribed $500M Series B Funding, Catapulting the Company’s Valuation to $4.2 Billion10.3.2026 13:45:00 CET | Press release
New Tier-1 Investors, Led by Lightspeed Venture Partners, Join to Fuel Development of Highly Efficient, Next-Generation AI and Cloud Networking Solutions Nexthop AI, the leading pioneer of highly efficient AI Networking, today announced successful closure of an oversubscribed $500 Million Series B funding round, catapulting the company’s valuation to $4.2 Billion. This round was spearheaded by Lightspeed Venture Partners, with Andreessen Horowitz joining as a major investor, and participation from Altimeter and all existing investors. “The rapid growth of AI is forcing a fundamental rethink of data center network architecture — and that creates one of the largest infrastructure market opportunities we’ve seen in a generation, with the potential to build a $100B+ company. That conviction led us to invest in Nexthop AI from Day One,” said Guru Chahal, Partner at Lightspeed Venture Partners. “Nexthop is uniquely positioned to become the next great networking vendor by combining hyperscale
Corpay Cross-Border Named Official Foreign Exchange Provider of the ABB FIA Formula E World Championship10.3.2026 13:30:00 CET | Press release
Delivering exclusive commercial FX solutions to the world’s premier all-electric racing series Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, today announced that its Cross-Border business has partnered with Formula E, the world’s first all-electric FIA World Championship and B Corp Certified sport. Under the agreement, Corpay becomes the exclusive and Official Foreign Exchange Provider of the ABB FIA Formula E World Championship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310640540/en/ The ABB FIA Formula E World Championship brings dramatic racing to the heart of some of the world’s most iconic cities providing an elite motorsport platform for the world’s leading automotive manufacturers to accelerate electric vehicle innovation with the GEN3 Evo race continuing to set a new benchmark as the fastest-accelerating FIA single-seater, rocketing from 0-60 mph in an astonishing 1.82 seconds. Through th
Wolters Kluwer Releases 2026 Future Ready Lawyer Survey Report, Highlighting Rapid AI Gains and Shifting Power Dynamics10.3.2026 13:00:00 CET | Press release
Global survey of legal professionals reveals strong momentum behind AI investment and workflow transformation Wolters Kluwer Legal & Regulatory has published the results of its global 2026 Future Ready Lawyer Survey, the preeminent source of insights from lawyers in law firms and corporate legal departments across the U.S., China and nine European countries. The findings show an industry coming to grips with the accelerated adoption of AI technology, an ambitious undertaking that has yielded long sought-after efficiencies across workflows and business practices, while raising unexpected challenges to ethics and infrastructure. “The Future Ready Lawyer global report has always reflected an industry in motion,” said Martin O'Malley, CEO of Wolters Kluwer Legal & Regulatory. “What’s most striking this year is how rapidly legal professionals are accelerating to meet that change by reshaping business models, rethinking long‑held dynamics, and embracing new ways to deliver value through both
Armis Announces Armis Centrix™ for Vulnerability Management Detection and Response to Reduce Cyber Risk and Eliminate Operational Friction10.3.2026 13:00:00 CET | Press release
Solution empowers organizations to continuously and accurately detect vulnerabilities across the entire attack surface, while reducing scan volume and impact Armis, the cyber exposure management & security company, today announced Armis Centrix™ for Vulnerability Management Detection and Response. The solution enables security teams to precisely identify and validate vulnerabilities across all of an organization’s assets in real time. Armis’ unified approach to vulnerability assessment results in greater accuracy, faster detection time and reduced operational costs. "Waiting weeks for a vulnerability scan that still misses essential assets is no longer sufficient to combat AI-powered cyberattacks,” said Nadir Izrael, CTO and Co-Founder at Armis. “Organizations need a continuous view of their complete environment to stay ahead of threats. Armis' new solution delivers more accurate, targeted results than traditional vulnerability management solutions with a fraction of the scans. It empo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom